Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5495-5504

  Linardakis, Emmanouela ^a   Bateman, Andrew ^a   Phan, Vy ^a   Ahmed, Atique ^a   Gough, Michael ^a   Olivier, Kenneth ^a   Kennedy, Rick ^b   Errington, Fiona ^c   Harrington, Kevin J ^d   Melcher, Alan ^c   Vile, Richard ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA VACCINE; RNA; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL FUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; IMMUNE SYSTEM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNCYTIUM; TUMOR; VACCINATION; VESICULAR STOMATITIS VIRUS;

3T3 CELLS; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL DEATH; CELL FUSION; COCULTURE TECHNIQUES; DENDRITIC CELLS; EGG PROTEINS; MACROPHAGE ACTIVATION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; OVALBUMIN; VIRAL ENVELOPE PROTEINS;

EID: 0036791104     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond.). 411: 380-384, 2001.
2. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
3. Nestle, F. O., Banchereau, J., and Hart, D. Dendritic cells: on the move from the bench to the bedside. Nat. Med., 7: 761-765, 2001.
4. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
5. Schadendorf, D., Paschen, A., and Sun, Y. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol. Lett., 74: 67-74, 2000.
6. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccines for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol., 19: 145-156, 2001.
7. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Muller, G. A., and Ringert, R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6: 332-336. 2000.
8. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshal, F. F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537-1546, 1997.
9. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lan, P., Mentzer, S., Singer, S., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L. K., Mulligan, R. C., and Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146, 1998.
10. Bystryn, J-C., Zeleniuch-Jacquotte, A., Oratz, R., Shapiro, R. L., Harris, M. N., and Roses, D. F. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res., 7: 1882-1887, 2001.
11. Patel, P. M., Flemming, C. L., Fisher, C., Porter, C. D., Thomas, J. M., Gore, M., and Collins, M. K. L. Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum. Gene Ther., 5: 577-584, 1994.
12. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Stemas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., and Kwak, L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 5: 1171-1177, 1999.
13. Berd, D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin. Biol. Ther., 2: 335-342, 2002.
14. Harris, J. E., Ryan, L., Hoover, H. C., Jr., Stuart, R. K., Oken, M. M., Benson, A. B., III, Mansour, E., Haller, D. G., Manola, J., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol, 18: 148-157, 2000.
15. Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J. J., and Srivastava, P. K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer, 88: 232-238, 2000.
16. Dalgleish, A. The case for therapeutic vaccines. Melanoma Res., 6: 5-10, 1996.
17. Morton, D. L., Hoon, D. S., Nizze, J. A., Foshag, L. J., Famatiga, E., Wanek, L. A., Chang, C., Irie, R. F., Gupta, R. K., and Elashoff, R. M. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann. NY Acad. Sci., 690: 120-134, 1993.
18. Habal, N., Gupta, R. K., Bilchik, A. J., Yee, R., Leopoldo, Z., Ye, W., Elashoff, R. M., and Morton, D. L. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol., 8: 389-401, 2001.
19. Fabre, J. W. The allogeneic response and tumor immunity. Nat. Med., 7: 649-652, 2001.
20. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science (Wash. DC), 264: 961-965, 1994.
21. Kurts, C., Miller, J. F. A. P., Subramaniam, R. M., Carbone, F. R., and Heath, W. R. Major histocompatibility complex class 1-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med., 188: 409-414, 1998.
22. Mitchell, D. A., Nair, S. K., and Gilboa, E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur. J. Immunol., 28: 1923-1933, 1998.
23. Suto, R., and Srivastava, P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Wash. DC), 269: 585-1588, 1995.
24. Castelli, C., Ciupitu, A. M., Rini, F., Rivoltini, L., Mazzocchi, A., Kiessling, R., and Parmiani, G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res., 61: 222-227, 2001.
25. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., and Zinkemagel, R. M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (Lond), 411: 1058-1064, 2001.
26. Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamanstein, T., and Blankenstein, T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res., 53: 714-716, 1993.
27. Melcher, A., Todryk, S., Bateman, A., Chong, H., Lemoine, N. R., and Vile, R. G. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res., 59: 2802-2805, 1999.
28. Todryk, S. M., Birchall, L. J., Erlich, R., Halanek, N., Orleans-Lindsay, J. K., and Dalgleish, A. G. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology, 102: 190-198, 2001.
29. Kayaga, J., Souberbielle, B., Sheikh, N., Morrow, W., Scott-Taylor, T., Vile, R., and Dalgleish, A. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther., 6: 1475-1481, 1999.
30. Peter, I., Mezzacasa, A., LeDonne, P., Dummer, R., and Hemmi, S. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res., 11: 21-30, 2001.
31. Bateman, A., Bullough, F., Murphy, S., Emiliusen, L., Lavillette, D., Cosset, F. L., Cattaneo, R., Russell, S. J., and Vile, R. G. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res., 60: 1492-1497, 2000.
32. Fielding, A. K., Chapel-Fernandes, S., Chadwick, M. P., Bullough, F. J., Cosset, F-L., and Russell, S. J. A hyperfusogenic Gibbon ape leukaemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum. Gene Ther., 11: 817-826, 2000.
33. Diaz, R. M., Bateman, A., Emiliusen, L., Fielding, A., Trono, D., Russell, S. J., and Vile, R. G. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther., 7: 1656-1663, 2000.
34. Suhy, D. A., Giddings, T. H., Jr., and Kirkegaard, K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J. Virol., 74: 8953-8965, 2000.
35. Melcher, A. A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4: 581-587, 1998.
36. Basu, S., Binder, R. J., Suto, R., Anderson, K. M., and Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol., 12: 1539-1546, 2000.
37. Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Amon, T. I., Bushkin, Y., Davis, D. M., Strominger, J. L., Yewdell, J. W., and Porgador, A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (Lond.), 409: 1055-1060, 2001.
38. Eslahi, N. K., Muller, S., Nguyen, L., Wilson, E., Thull, N., Rolland, A., and Pericle, F. Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy. Cancer Gene Ther., 8: 55-62, 2001.
39. Schirrmacher, V., Haas, C., Bonifer, R., Ahlert, T., Gerhards, R., and Ertel, C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther., 6: 63-73, 1999.
40. Gough, M. J., Melcher, A. A., Ahmed, A., Crittenden, M. R., Riddle, D. S., Linardakis, E., Ruchatz, A. N., and Vile, R. G. Macrophages orchestrate the immune response to tumor cell death. Cancer Res., 61: 7240-7247, 2001.
41. Melcher, A. A., Gough, M. J., Todryk, S., and Vile, R. G. Apoptosis or necrosis for tumour immunotherapy-what's in a name? J. Mol. Med., 77: 824-833, 1999.
42. Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., and Bhardwaj, N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191: 423-434, 2000.
43. Matzinger, P. Tolerance, danger and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.
44. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.
45. Chong, H., Hutchinson, G., Hart, I. R., and Vile, R. G. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic anti-tumor immunity. Hum. Gene Ther., 7: 1771-1779, 1996.
46. Castleden, S. A., Chong, H., Garcia-Ribas, I., Melcher, A. A., Hutchinson, G., Roberts, B., Hart, I. R., and Vile, R. G. A family of bicistronic vectors to enhance both local and systemic anti tumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther., 8: 2087-2102, 1997.
47. Chong, H., Todryk, S., Hutchinson, G., Hart, I. R., and Vile, R. G. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther., 5: 223-232, 1998.
48. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helperfree packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
49. Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., and Vile, R. G. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol., 163: 1398-1408, 1999.
50. Fredericksen, B. L., and Whitt, M. A. Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J. Virol., 69: 1435-1443, 1995.
51. Inaba, K., Inaba, M., Romani, M., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte macrophage colony stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
52. Hogquist, K. A., Jameson, S. C., Health, W. R., Howard, J. L., Bevan, M. J., and Carbone, F. R. T cell receptor antagonistic peptides induce positive selection. Cell. 76: 17-27, 1994.
53. Altman, D. G. Analysis of survival times. In: D. G. Altman (ed.), Practical Statistics for Medical Research, pp. 365-395, Chapman and Hall, London, 1991.
54. Han, X., Bushweller, J. H., Cafiso, D. S., and Tamm, L. K. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin. Nat. Struct. Biol., 8: 715-720, 2001.
55. Wang, J., Saffold, S., Cao, X., Krauss, J., and Chen, W. Eliciting T cell immunity against poorly immunogenic tumors by immunisation with dendritic cell-tumor fusion vaccines. J. Immunol., 161: 5516-5524, 1998.
56. Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., and Musiani, P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97: 339-345, 2001.
57. Prehn, R. T. Two competing influences that may explain concomitant tumor resistance. Cancer Res., 53: 3266-3269, 1993.
58. Cavallo, F., Giovarrelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Modesti, A., and Forni, G. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to non immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfer. J. Immunol., 149: 3627-3635, 1992.
59. Cayeux, S., Richter, G., Becker, C., Pezzutto, A., Dorken, B., and Blankenstein, T. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol., 29: 255-234, 1999.
60. Huang, A. Y. C., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. In vivo crosspriming of MHC Class I-restricted antigens requires a TAP transporter. Immunity, 4: 349-355, 1996.
61. Forni, G., Lollini, P. L., Musiani, P., and Colombo, M. P. Immunoprevention of cancer: is the time ripe? Cancer Res., 60: 2571-2575, 2000.
62. Gallucci, S., Lolkema, M., and Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med., 5: 1249-1255, 1999.
63. Higuchi, H., Bronk, S., Bateman, A., Harrington, K. J., Vile, R. G., and Gores, G. J. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res., 60: 6396-6402, 2000.
64. Staib, L., Harel, W., and Mitchell, M. S. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization. Cancer Res., 53: 1113-1121, 1993.
65. Kim, B. S. Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma. J. Immunol., 123: 739-744, 1979.
66. Payelle, B., Poupon, M. F., and Lespinats, G. Adoptive transfer of immunity induced by semi-allogeneic hybrid cells, against a murine fibrosarcoma. Int. J. Cancer. 27: 783-788, 1981.
67. Toffaletti, D. L., Darrow, T. L., and Scott, D. W. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids. J. Immunol., 130: 2982-2986, 1983.
68. Newton, D. A., Romano, C., and Gattoni-Celli, S. Semiallogeneic cell hybrids as therapeutic vaccines for cancer. J. Immunother., 23: 246-254, 2000.
69. Newton, D. A., Acierno, P. M., Metts, M. C., Baron, P. L., Brescia, F. J., and Gattoni-Celli, S. Semiallogeneic cancer vaccines formulated with granulocytemacrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot Phase I study. J. Immunother., 24: 19-26, 2001.
70. Harris, H., and Watkins, J. F. Hybrid cells derived from mouse and man: artificial heterokaryons of mammalian cells from different species. Nature (Lond.), 205: 640-646, 1965.
71. Watkins, J. F., and Chen, L. Immunization of mice against Ehrlich ascites tumour using a hamster/Ehrlich ascites tumour hybrid cell line. Nature (Lond.), 223: 1018-1022, 1969.
72. Guo, Y., Wu, M., Chen, H., Wang, X., Liu, G., Li, G., Ma, J., and Sy, M-S. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science (Wash. DC). 263: 518-520, 1994.
73. Mitchison, N. A., and O'Malley, C. Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur. J. Immunol., 17: 1579-1583, 1987.
74. Castellino, F., Boucher, P. E., Eichelberg, K., Mayhew, M. Rothman, J. E., Houghton, A. N., and Germain, R. N. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med., 191: 1957-1964, 2000.
75. Singh-Jasuja, H., Toes, R. E., Spee, P., Munz, C., Hilf, N., Schoenberger, S. P., Ricciardi-Castagnoli, P., Neefjes, J., Rammensee, H. G., Arnold-Schild, D., and Schild, H. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med., 191: 1965-1974, 2000.
76. Basu, S., Binder, R. J., Ramalingam, T., and Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 14: 303-313, 2001.
77. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Wash. DC), 278: 117-120, 1997.
78. Bellone, M., Iezzi, G., Rovere, P., Galati, G., Ronchetti, A., Protti, M. P., Davoust, J., Rugarli, C., and Manfredi, A. A. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol., 159: 5391-5399, 1997.
79. Buschle, M., Schmidt, W., Zauner, W., Mechtler, K., Trska, B., Kirlappos, H., and Birnstiel, M. L. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA. 94: 3256-3261, 1997.
80. Hirt, U. A., Gantner, F., and Leist, M. Phagocytosis of nonapoptotic cells dying by caspase-independent mechanisms. J. Immunol., 164: 6520-6529, 2000.
81. Diaz, R. M., Todryk, S., Chong, H., Hart, I., R., Sikora, K., Dorudi, S., and Vile, R. G. Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther., 5: 869-879, 1998.